Wolfe Research Downgrades Corcept Therapeutics (CORT) to Underperform

July 27, 2026 1:22 AM

Wolfe Research analyst Kalpit Patel downgraded Corcept Therapeutics (NASDAQ: CORT) from Peerperform to Underperform with a price target of $50.00.The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found